IDEAS home Printed from https://ideas.repec.org/a/spr/hecrev/v14y2024i1d10.1186_s13561-024-00479-6.html
   My bibliography  Save this article

Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China

Author

Listed:
  • Pingyu Chen

    (China Pharmaceutical University
    China Pharmaceutical University)

  • Mengjie Luo

    (China Pharmaceutical University)

  • Yanqiu Chen

    (China Pharmaceutical University)

  • Yanlei Zhang

    (State Key Laboratory of Neurology and Oncology Drug Development (Jiangsu Simcere Pharmaceutical Co.,Ltd., Jiangsu Simcere Diagnostics Co.,Ltd.))

  • Chao Wang

    (State Key Laboratory of Neurology and Oncology Drug Development (Jiangsu Simcere Pharmaceutical Co.,Ltd., Jiangsu Simcere Diagnostics Co.,Ltd.))

  • Hongchao Li

    (China Pharmaceutical University
    China Pharmaceutical University)

Abstract

Background Clinical trials have demonstrated the efficacy of edaravone dexborneol in the treatment of acute ischemic stroke. This study aims to determine the cost-effectiveness of edaravone dexborneol compared with human urinary kallidinogenase from China’s healthcare system perspective. Methods A combination of the decision tree and Markov model was constructed to evaluate the cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase in the treatment of acute ischemic stroke over a lifetime horizon. Efficacy data were derived from pivotal clinical trials of edaravone dexborneol and human urinary kallidinogenase (TASTE trial and RESK trial, respectively) and adjusted using matching-adjusted indirect comparison. Cost and health utility inputs were extracted from published literature and open databases. One-way deterministic sensitivity and probabilistic sensitivity analyses were performed to examine the robustness of the results. Results Compared with human urinary kallidinogenase, edaravone dexborneol generated 0.153 incremental quality-adjusted life years (QALYs) with an incremental cost of ¥856, yielding an incremental cost-effectiveness ratio of ¥5,608 per QALY gained under the willingness-to-pay threshold (one-time gross domestic product per capita). Both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis demonstrated the robustness of the base case results. Conclusions Edaravone dexborneol is a cost-effective treatment choice for acute ischemic stroke patients compared with human urinary kallidinogenase in China.

Suggested Citation

  • Pingyu Chen & Mengjie Luo & Yanqiu Chen & Yanlei Zhang & Chao Wang & Hongchao Li, 2024. "Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China," Health Economics Review, Springer, vol. 14(1), pages 1-10, December.
    • Handle: RePEc:spr:hecrev:v:14:y:2024:i:1:d:10.1186_s13561-024-00479-6
    DOI: 10.1186/s13561-024-00479-6
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1186/s13561-024-00479-6
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1186/s13561-024-00479-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Weiyi Ni & Wolfgang G. Kunz & Mayank Goyal & Lijin Chen & Yawen Jiang, 2022. "Quality of life and cost consequence of delays in endovascular treatment for acute ischemic stroke in China," Health Economics Review, Springer, vol. 12(1), pages 1-8, December.
    2. David M. Phillippo & Anthony E. Ades & Sofia Dias & Stephen Palmer & Keith R. Abrams & Nicky J. Welton, 2018. "Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal," Medical Decision Making, , vol. 38(2), pages 200-211, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Manuel Gomes & Nick Latimer & Marta Soares & Sofia Dias & Gianluca Baio & Nick Freemantle & Dalia Dawoud & Allan Wailoo & Richard Grieve, 2022. "Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges," PharmacoEconomics, Springer, vol. 40(6), pages 577-586, June.
    2. B. Muresan & C. Mamolo & J. C. Cappelleri & M. J. Postma & B. Heeg, 2021. "Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting," Applied Health Economics and Health Policy, Springer, vol. 19(6), pages 929-940, November.
    3. Dasom Lee & Shu Yang & Lin Dong & Xiaofei Wang & Donglin Zeng & Jianwen Cai, 2023. "Improving trial generalizability using observational studies," Biometrics, The International Biometric Society, vol. 79(2), pages 1213-1225, June.
    4. Lu Han & Kuixu Lan & Dejian Kou & Zehua Meng & Jin Feng & Elizabeth Maitland & Stephen Nicholas & Jian Wang, 2024. "Cost-effectiveness of endovascular treatment for acute ischemic stroke in China: evidence from Shandong Peninsula," Health Economics Review, Springer, vol. 14(1), pages 1-9, December.
    5. Alex J. Turner & Cormac Sammon & Nick Latimer & Blythe Adamson & Brennan Beal & Vivek Subbiah & Keith R. Abrams & Joshua Ray, 2024. "Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments," PharmacoEconomics, Springer, vol. 42(2), pages 165-176, February.
    6. Jiyeon Kang & John Cairns, 2023. "“Don’t Think Twice, It’s All Right”: Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England," PharmacoEconomics - Open, Springer, vol. 7(1), pages 77-91, January.
    7. Sanjay Popat & Stephen V. Liu & Nicolas Scheuer & Grace G. Hsu & Alexandre Lockhart & Sreeram V. Ramagopalan & Frank Griesinger & Vivek Subbiah, 2022. "Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    8. Nan Qiao & Ralph Insinga & Thomas Burke & Gilberto Lopes, 2021. "Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Per," PharmacoEconomics - Open, Springer, vol. 5(4), pages 765-778, December.
    9. Doug Coyle & Isabelle Durand-Zaleski & Jasmine Farrington & Louis Garrison & Johann-Matthias Graf von der Schulenburg & Wolfgang Greiner & Louise Longworth & Aurélie Meunier & Anne-Sophie Moutié & Ste, 2020. "HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(9), pages 1421-1437, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:hecrev:v:14:y:2024:i:1:d:10.1186_s13561-024-00479-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/13561 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.